Overview

Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.

Phase:

Phase 2

Details

Lead Sponsor:

Dong-A ST Co., Ltd.

Treatments:

Lenograstim